| Literature DB >> 26366072 |
Thomas Ringbæk1, Allan Green2, Lars Christian Laursen3, Ejvind Frausing2, Eva Brøndum2, Charlotte Suppli Ulrik1.
Abstract
BACKGROUND ANDEntities:
Keywords: COPD; admissions; exacerbations; tele health care; video consultations
Mesh:
Substances:
Year: 2015 PMID: 26366072 PMCID: PMC4562759 DOI: 10.2147/COPD.S85596
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Baseline characteristic of the patients (n=281) enrolled in the tele health care study divided according to the group assignment
| Tele monitoring, N=141 | Controls, N=140 | ||
|---|---|---|---|
| Females, N (%) | 86 (61%) | 63 (45%) | 0.007 |
| Age, years | 69.8 (9.0) | 69.4 (10.1) | 0.75 |
| BMI, kg/m2 | 24.9 (6.3) | 26.9 (7.0) | 0.013 |
| FEV1 %pred | 34.9 (13.3) | 33.8 (12.0) | 0.48 |
| MRC dyspnea score, mean (range) | 3.5 (2–5) | 3.7 (1–5) | 0.09 |
| Current smokers, N (%) | 35 (24.8%) | 47 (33.6%) | 0.10 |
| Pack years, mean (range) (N=133/116) | 42.9 (0–210) | 41.0 (0–110) | 0.72 |
| Long-term oxygen therapy, N (%) | 37 (26.2%) | 38 (27.1%) | 0.86 |
| Charlson Comorbidity Index | 1.70 (1.49) | 1.96 (1.51) | 0.13 |
| Living alone, % | 57.9% | 52.2% | NS |
| Hospital admissions for COPD exacerbation in the year prior to enrollment, mean (range) | 1.41 (0–7) | 1.22 (0–23) | 0.61 |
| Medication for COPD, N (%) | |||
| Oral prednisolone | 10 (7.1%) | 14 (10.0%) | 0.68 |
| Roflumilast | 8 (5.7%) | 5 (3.6%) | 0.39 |
| Inhaled corticosteroids | 129 (91.5%) | 128 (91.4%) | 0.57 |
| Long-acting antimuscarinic agents | 131 (92.9%) | 120 (85.7%) | 0.99 |
| Long-acting β2-agonists | 134 (95.0%) | 136 (97.1%) | 0.54 |
Notes: Values are mean (and standard deviation) unless otherwise specified. All P-values are comparisons between the TM and control group.
Data missing for one patient;
data missing for patients 8 and 24, respectively.
maintenance therapy.
Abbreviations: FEV1, forced expiratory volume in 1 second; MRC, Medical Research Council; TM, tele monitoring; NS, not significant.
Figure 1Flowchart of patients with COPD identified as eligible for inclusion into the study investigating the effect of add-on tele health care, including video consultations, to standard care on hospital admissions for COPD.
Frequency and characteristics of acute exacerbations, hospital admissions, and visits to emergency rooms and outpatient clinics for tele monitored patients and controls
| Tele monitoring, N=141 | Controls, N=140 | ||
|---|---|---|---|
| Hospital admission for COPD exacerbation, mean (range) | 0.55 (0–5) | 0.54 (0.4) | 0.74 |
| All cause hospital admissions, mean (range) | 1.19 (0–12) | 1.31 (0–9) | 0.28 |
| At least one hospitalization (any cause), % | 46.8% | 51.4% | 0.44 |
| Length of stay, all-cause hospital admissions (days), mean (range) | 5.35 (0–71) | 5.29 (0–53) | 0.38 |
| At least one COPD exacerbation requiring hospital admission, % | 29.1% | 31.4% | 0.67 |
| Length of stay, COPD hospital admissions (days), mean (range) | 1.76 (0–52) | 2.02 (0–31) | 0.51 |
| Exacerbation of COPD not requiring hospital admission, | 1.21 (0–17) | 0.73 (0–8) | 0.001 |
| At least one exacerbation of COPD not requiring hospitalization | 58.2% | 37.1% | <0.001 |
| Visits to the emergency room, mean (range) | 0.11 (0–3) | 0.16 (0–2) | 0.12 |
| Visits to the respiratory outpatient clinic, mean (range) | 0.26 (0–3) | 0.99 (0–7) | <0.001 |
| Visits to nonrespiratory outpatient clinics, mean (range) | 1.34 (0–12) | 1.41 (0–10) | 0.43 |
Note:
An exacerbation was defined as a worsening of COPD symptoms requiring treatment with a rescue course of systemic corticosteroids and/or antibiotics.
Figure 2Hospital admission for COPD during the 6-month study period for patients randomized to tele health care + standard care (TM group, n=141) vs standard care (control group, n=140).
Abbreviation: TM, tele monitoring.
Figure 3All-cause hospital admission during the 6-month study period for patients randomized to tele health care + standard care (TM group, n=141) vs standard care (control group, n=140).
Abbreviation: TM, tele monitoring.